Stryker (NYSE:SYK) Issues Quarterly Earnings Results

Stryker (NYSE:SYK) announced its quarterly earnings results on Thursday. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20, Zacks reports. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the firm earned $3.13 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Stryker updated its FY 2026 guidance to 14.950-15.100 EPS.

Here are the key takeaways from Stryker’s conference call:

• Organic sales grew 9% in Q2, with high-single-digit growth in both MedSurg and Neurotechnology and Orthopaedics, while adjusted EPS increased 17.9% to $3.69.
• Strong demand for capital equipment produced an elevated backlog, and Stryker expects production recovery and fulfillment of orders to support a stronger second half.
• Mako installations reached a quarterly record, with rising utilization and the full U.S. launch of handheld Mako RPS adding to the company’s robotics growth opportunity; several other product launches also received positive customer feedback.
• Peripheral Vascular sales were hurt by a supply disruption at an Inari manufacturing plant, creating significant backorders and lost sales; the company expects improvement but said growth will take time to rebuild.
• Stryker narrowed 2026 guidance to 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10, citing cybersecurity-related remediation and manufacturing costs despite improved margins and a planned resumption of share repurchases.

Stryker Stock Down 1.1%

Shares of NYSE:SYK traded down $3.88 during trading on Thursday, hitting $348.37. The stock had a trading volume of 2,766,545 shares, compared to its average volume of 2,241,684. The company has a market capitalization of $133.55 billion, a PE ratio of 40.32, a PEG ratio of 2.26 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The firm’s fifty day moving average is $317.08 and its 200 day moving average is $334.98. Stryker has a 12 month low of $281.00 and a 12 month high of $401.99.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio is currently 40.74%.

Analyst Ratings Changes

Several analysts recently issued reports on SYK shares. Evercore set a $350.00 target price on Stryker in a research note on Monday, July 6th. BTIG Research set a $371.00 price objective on Stryker in a report on Monday, July 13th. Leerink Partners cut their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. JPMorgan Chase & Co. reduced their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, Needham & Company LLC decreased their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $393.39.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last ninety days. Company insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently bought and sold shares of the business. United Financial Planning Group LLC bought a new position in shares of Stryker during the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the 4th quarter worth approximately $27,000. Strive Asset Management LLC bought a new position in Stryker during the 3rd quarter valued at approximately $30,000. Birchwood Financial Partners Inc. purchased a new position in Stryker during the fourth quarter valued at $35,000. Finally, Kemnay Advisory Services Inc. purchased a new position in Stryker during the fourth quarter valued at $49,000. Institutional investors own 77.09% of the company’s stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter adjusted earnings of $3.69 per share, ahead of estimates ranging from $3.46 to $3.49 and up from $3.13 a year earlier. Revenue reached $6.59 billion, narrowly exceeding expectations and increasing 9.4% year over year. Stryker Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Strong demand for implants and devices used in complex spinal and orthopedic procedures supported the quarterly results, indicating resilient underlying demand for Stryker’s medical technology products. Stryker Beats Quarterly Estimates on Strong Demand
• Positive Sentiment: Management provided full-year 2026 EPS guidance of $14.95 to $15.10, broadly above the current analyst consensus of approximately $14.98, supporting expectations for continued earnings growth.
• Positive Sentiment: UBS initiated coverage with a Buy rating and a $400 price target, implying meaningful upside from recent trading levels and adding a new bullish analyst view. UBS Initiates Stryker Coverage
• Neutral Sentiment: Stryker reported approximately $1.28 billion in profit and said it is making progress recovering from a March cyberattack. However, the recovery remains an operational consideration for investors. Stryker Logs Higher Profit Amid Cyberattack Recovery
• Negative Sentiment: Medical-product companies continue to face potential margin pressure from tariffs and inflation. That concern may temper the market’s reaction to Stryker’s earnings beat, particularly given the stock’s elevated valuation.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.